ScienceDaily (Oct. 1, 2012) An experimental treatment for blindness, developed from a patient's skin cells, improved the vision of blind mice in a study conducted by Columbia ophthalmologists and stem cell researchers. <\/p>\n
The findings suggest that induced pluripotent stem (iPS) cells -- which are derived from adult human skin cells but have embryonic properties -- could soon be used to restore vision in people with macular degeneration and other diseases that affect the eye's retina. <\/p>\n
\"With eye diseases, I think we're getting close to a scenario where a patient's own skin cells are used to replace retina cells destroyed by disease or degeneration,\" says the study's principal investigator, Stephen Tsang, MD, PhD, associate professor of ophthalmology and pathology & cell biology. \"It's often said that iPS transplantation will be important in the practice of medicine in some distant future, but our paper suggests the future is almost here.\" <\/p>\n
The advent of human iPS cells in 2007 was greeted with excitement from scientists who hailed the development as a way to avoid the ethical complications of embryonic stem cells and create patient-specific stem cells. Like embryonic stem cells, iPS cells can develop into any type of cell. Thousands of different iPS cell lines from patients and healthy donors have been created in the last few years, but they are almost always used in research or drug screening. <\/p>\n
No iPS cells have been transplanted into people, but many ophthalmologists say the eye is the ideal testing ground for iPS therapies. <\/p>\n
\"The eye is a transparent and accessible part of the central nervous system, and that's a big advantage. We can put cells into the eye and monitor them every day with routine non-invasive clinical exams,\" Tsang says. \"And in the event of serious complications, removing the eye is not a life-threatening event.\" <\/p>\n
In Tsang's new preclinical iPS study, human iPS cells -- derived from the skin cells of a 53-year-old donor -- were first transformed with a cocktail of growth factors into cells in the retina that lie underneath the eye's light-sensing cells. <\/p>\n
The primary job of the retina cells is to nourish the light-sensing cells and protect the fragile cells from excess light, heat, and cellular debris. If the retina cells die -- which happens in macular degeneration and retinitis pigmentosa -- the photoreceptor cells degenerate and the patient loses vision. Macular degeneration is a leading cause of vision loss in the elderly, and it is estimated that 30 percent of people will have some form of macular degeneration by age 75. Macular degeneration currently affects 7 million Americans and its incidence is expected to double by 2020. <\/p>\n
In their study, the researchers injected the iPS-derived retina cells into the right eyes of 34 mice that had a genetic mutation that caused their retina cells to degenerate. <\/p>\n
In many animals, the human cells assimilated into mouse retina without disruption and functioned as normal retina cells well into the animals' old age. Control mice that got injections of saline or inactive cells showed no improvement in retina tests. <\/p>\n<\/p>\n
See original here: ScienceDaily (Oct. 1, 2012) An experimental treatment for blindness, developed from a patient's skin cells, improved the vision of blind mice in a study conducted by Columbia ophthalmologists and stem cell researchers. The findings suggest that induced pluripotent stem (iPS) cells -- which are derived from adult human skin cells but have embryonic properties -- could soon be used to restore vision in people with macular degeneration and other diseases that affect the eye's retina. \"With eye diseases, I think we're getting close to a scenario where a patient's own skin cells are used to replace retina cells destroyed by disease or degeneration,\" says the study's principal investigator, Stephen Tsang, MD, PhD, associate professor of ophthalmology and pathology & cell biology. \"It's often said that iPS transplantation will be important in the practice of medicine in some distant future, but our paper suggests the future is almost here.\" The advent of human iPS cells in 2007 was greeted with excitement from scientists who hailed the development as a way to avoid the ethical complications of embryonic stem cells and create patient-specific stem cells. Like embryonic stem cells, iPS cells can develop into any type of cell. Thousands of different iPS cell lines from patients and healthy donors have been created in the last few years, but they are almost always used in research or drug screening. No iPS cells have been transplanted into people, but many ophthalmologists say the eye is the ideal testing ground for iPS therapies. \"The eye is a transparent and accessible part of the central nervous system, and that's a big advantage. We can put cells into the eye and monitor them every day with routine non-invasive clinical exams,\" Tsang says. \"And in the event of serious complications, removing the eye is not a life-threatening event.\" In Tsang's new preclinical iPS study, human iPS cells -- derived from the skin cells of a 53-year-old donor -- were first transformed with a cocktail of growth factors into cells in the retina that lie underneath the eye's light-sensing cells. The primary job of the retina cells is to nourish the light-sensing cells and protect the fragile cells from excess light, heat, and cellular debris. If the retina cells die -- which happens in macular degeneration and retinitis pigmentosa -- the photoreceptor cells degenerate and the patient loses vision. Macular degeneration is a leading cause of vision loss in the elderly, and it is estimated that 30 percent of people will have some form of macular degeneration by age 75. Macular degeneration currently affects 7 million Americans and its incidence is expected to double by 2020. In their study, the researchers injected the iPS-derived retina cells into the right eyes of 34 mice that had a genetic mutation that caused their retina cells to degenerate. In many animals, the human cells assimilated into mouse retina without disruption and functioned as normal retina cells well into the animals' old age. Control mice that got injections of saline or inactive cells showed no improvement in retina tests. Continue reading
\nStem cells improve visual function in blind mice<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"